GSK3β is strongly implicated in dementia and ALS and so GSK3β inhibitors may prove to be therapeutic for FTD/ALS (Llorens-Martin et al., 2014; Lauretti et al., 2020). This evidence concerns the gene GSK3B and amyotrophic lateral sclerosis.